Compare PVH & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PVH | CELC |
|---|---|---|
| Founded | 1881 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.1B |
| IPO Year | 1994 | 2017 |
| Metric | PVH | CELC |
|---|---|---|
| Price | $92.03 | $125.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 9 |
| Target Price | $90.53 | ★ $112.56 |
| AVG Volume (30 Days) | ★ 1.2M | 665.8K |
| Earning Date | 06-03-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.16% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $8,950,200,000.00 | N/A |
| Revenue This Year | $1.89 | N/A |
| Revenue Next Year | $1.86 | $720.19 |
| P/E Ratio | $176.37 | ★ N/A |
| Revenue Growth | ★ 3.44 | N/A |
| 52 Week Low | $59.60 | $9.64 |
| 52 Week High | $100.15 | $129.09 |
| Indicator | PVH | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 62.01 | 57.27 |
| Support Level | $72.61 | $100.58 |
| Resistance Level | $100.15 | N/A |
| Average True Range (ATR) | 3.41 | 7.28 |
| MACD | -0.98 | -0.10 |
| Stochastic Oscillator | 45.23 | 86.78 |
PVH designs and markets branded apparel in more than 40 countries. Its key fashion categories include men's dress shirts, ties, sportswear, underwear, and jeans. Its two designer brands, Calvin Klein and Tommy Hilfiger, now generate practically all its revenue after its recent disposition of most of its smaller brands. PVH operates e-commerce sites, roughly 1,400 standalone stores, and about 1,500 shop-in-shops and concessions. The firm also licenses its brands to third parties and distributes its merchandise through department stores and other wholesale accounts. PVH traces its history to 1881 and is based in New York City.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.